ALiEM - Pharm Pearls

FEBRUARY 16, 2024

An 86-year-old man with a past medical history of coronary artery disease, hypertension, hyperlipidemia, chronic kidney disease, COPD, choledocholithiasis requiring ERCP and sphincterotomy 2 years ago presented with five days of feeling unwell. View other cases from this Clinical Image Series on ALiEM.

Hospitals 158

Hospitals 158

European Pharmaceutical Review

NOVEMBER 21, 2023

If successful this could lead to regulatory submissions in 2025, supporting the health of asthma and COPD patients and making a significant positive impact on our transition to a more environmentally sustainable future,” GSK’s Chief Executive Officer, Emma Walmsley commented.

111

111

Pharmacy Is Right For Me

FEBRUARY 22, 2024

Joining the Family Medicine Clinic during his residency provided Mohanad with exposure to ambulatory care, where he found his impact and strong fit immediately. These encounters can take place in the clinic, via telephone, or through Telemedicine.

Community Pharmacies 130

Community Pharmacies Scheduling Appointments Diabetes Hospitals 130

pharmaphorum

NOVEMBER 19, 2021

More than 100 million Americans affected by COPD, COVID-19 and asthma. “There is a clear difference in the acoustic resonance spectra of COPD patients versus healthy controls,” she added. “She suffered from COPD and had a sudden exacerbation of her symptoms and tragically died.

Hospitals 120

Hospitals 120

pharmaphorum

MARCH 11, 2021

Unlocking the clinical value of the EHR with AI and Big Data whist ensuring the safety of patient data at all times. Dr Ignacio H Medrano, CMO and founder, Savana is a consultant neurologist with training in healthcare management and experience in clinical research strategies – formerly responsible for +500 researchers.

108

108

Med Ed 101

APRIL 3, 2022

Asthma and COPD are two disease states that we need to use inhalers. As a clinical pharmacist, I understand the importance of patient education. I’ve seen numerous mistakes with inhaler technique over the years in my practice as a clinical pharmacist. Here are some of those examples.

45

45

Med Ed 101

MARCH 27, 2022

COPD is a challenging disease that ultimately leads to a progressive reduction in lung function. Roflumilast (podcast) is a unique medication for COPD in that it is taken orally. I want to discuss roflumilast clinical pearls and where this medication might be […].

40

40

Pharmafile

APRIL 11, 2023

Published date: 11/04/2023 Summary: LONDON and RALEIGH, N.C., LONDON and RALEIGH, N.C., read more LONDON and RALEIGH, N.C., read more

40

40

pharmaphorum

AUGUST 14, 2020

Based in the UK and US, Verona is due to start a phase 3 trial of ensifentrine in chronic obstructive pulmonary disease (COPD) later this year after encouraging results in phase 2. Zaccardelli took over as CEO in February, replacing Jan-Anders Karlsson, who retired after eight years to pursue non-executive roles.

Compounding 109

Compounding 109

pharmaphorum

NOVEMBER 14, 2022

Sanofi and Regeneron are running a phase 3 trial of the drug in COPD patients with type 2 inflammation called NOTUS that is due to generate results next year. Sanofi and Regeneron have predicted that Dupixent could make around $13 billion a year at peak, which would propel the drug into the top five biggest pharmaceutical sellers.

Immunity 115

Immunity Immunization 115

Pharmaceutical Technology

NOVEMBER 28, 2022

Under the agreement, AstraZeneca will be responsible for the development and marketing of oral therapy for inflammatory and respiratory diseases with a key focus on chronic obstructive pulmonary disease (COPD). This includes an upfront payment of $2m from AstraZeneca. Additionally, AstraZeneca will make a potential payment of $385.8m

Immunity 105

Immunity Immunization 105

Putting Patients First Blog

SEPTEMBER 19, 2023

Hess, MPH, RRT, RPFT, Senior Director of Public Outreach and Education, COPD Foundation Supplemental oxygen therapy has been an essential therapy for chronic breathing problems for decades. From chronic obstructive pulmonary disease (COPD) to pulmonary fibrosis to pneumonia, giving someone extra oxygen can be — literally — lifesaving.

Hospitals 59

Hospitals Inpatient 59

Pharmaceutical Technology

SEPTEMBER 5, 2022

An example of AstraZeneca’s deals in the cardiovascular disease clinical landscape is its agreement with US-based Dogma Therapeutics. In 2021, AstraZeneca sold $270 million worth of assets to Covis Pharma, which then transferred AstraZeneca’s chronic obstructive pulmonary disease (COPD) inhalers Tudorza and Duaklir to Covis.

Vaccines 114

Vaccines 114

pharmaphorum

DECEMBER 19, 2022

It would provide an alternative to standard breathing exercises for patients with conditions that affect breathing, including long-term respiratory diseases like asthma, chronic obstructive pulmonary disorder (COPD) and cystic fibrosis, which can be resource-intensive as they require patients to be overseen by a healthcare worker.

145

145

pharmaphorum

FEBRUARY 2, 2021

UK-based Verona Pharma has scored a new win with its chronic obstructive pulmonary disease (COPD) drug ensifenitrine, after a formulation delivered with an inhaler met its goals in a phase 2 trial. The post Boost for Verona Pharma after trial win with inhaled COPD drug appeared first on.

Compounding 40

Compounding 40

Pulses

SEPTEMBER 19, 2023

1 With this competitive job market, it is important that we equip our students with the skills needed to succeed in interviews as well as in clinical practice. I remember one challenging patient who hadn’t been using her maintenance COPD inhalers as they were too expensive.

Communication 59

Communication 59

PharmaShots

JUNE 13, 2023

AstraZeneca announces Results of AERISTO P-IIIb trial for Bevespi Aerosphere in COPD patients Published: 23Aug,2018 | Tags: AstraZeneca, Announces, AERISTO P-IIIb, Bevespi Aerosphere, COPD 4. AbbVie Exercises Exclusive Option to License Argenx's ARGX-115 Published: 22 Aug,2018 | Tags: AbbVie, Argenx, Option to License, ARGX-115 8.

Biosimilars 52

Biosimilars Labelling Diabetes 52

Pharmacy Joe

AUGUST 16, 2023

The decision to intubate is often based on clinical experience as much as it is based on objective data. What is the anticipated clinical course? COPD exacerbation, asthma exacerbation, and acute pulmonary edema are examples of conditions where a patient might not be able to oxygenate. Can the patient protect their airway?

Hospitals 98

Hospitals Inpatient Labelling 98

pharmaphorum

OCTOBER 26, 2022

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis and other interstitial lung diseases (ILDs). ” The post Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3 appeared first on.

Labelling 98

Labelling 98

pharmaphorum

JANUARY 17, 2023

Unify, launched in December 2020, is AstraZeneca’s patient app and clinical trial support tool. Attrition in drug development for chronic disease is high, often because the wrong patients are selected for clinical trials,” Challis explained. Digital technology and ‘frictionless’ clinical trials. Dissecting heterogeneity.

Drug Development 98

Drug Development 98

Med Ed 101

DECEMBER 11, 2019

These agents have been commonly used in the setting of asthma and COPD. The post The Clinical Difference Between Salmeterol and Formoterol appeared first on Med Ed 101. Each of these agents is most commonly combined with an inhaled corticosteroid. Budesonide is coupled with formoterol in the brand name product Symbicort.

40

40

pharmaphorum

FEBRUARY 11, 2021

The generic respiratory drug budesonide could be an option to treat COVID-19, a small scale clinical study has suggested. Researchers decided to begin the trial after noticing that people with asthma or chronic obstructive pulmonary disease (COPD) were surprisingly underrepresented among patients hospitalised with COVID-19.

98

98

The Digital Apothecary

JULY 10, 2016

Drug Delivery Products List Inhalers The over all premise behind the use of digital health technologies in inhalers is that it offers a means for providers to see when and how often patients are using their treatment for asthma or COPD. Propeller Health - Currently in partnership with UK Vectura and GSK.

Diabetes 130

Diabetes Pharmaceutical Companies Pharmaceutical Companies Hospitals 130

pharmaphorum

APRIL 14, 2022

ResApp’s technology was created to detect a wide range of respiratory conditions such as pneumonia, asthma, bronchiolitis and chronic obstructive pulmonary disease (COPD) using only the sound of a patient’s cough.

73

73

pharmaphorum

JUNE 17, 2022

It’s also possible that the big pharma is interested in Mereo ‘s other clinical-stage candidates, such as its anti-TIGIT antibody etigilimab which is being tested for cancer alongside PD-1/PD-L1 inhibitors.

Diabetes 80

Diabetes 80

Pharmaceutical Technology

APRIL 26, 2023

Dr. Amy Chan, senior clinical research fellow at the School of Pharmacy, University of Auckland, says digital inhalers have existed for almost 30 years. In a 2020 study, Chan found devices that can easily calculate adherence to activation and inhalation could have the greatest utility in clinical practice.

Medication Delivery 115

Medication Delivery Communication Drug Development 115

pharmaphorum

MARCH 27, 2022

The two companies say they plan to launch a series of Software as a Medical Device (SaMD) companion apps for various diseases, including asthma, chronic obstructive pulmonary disease (COPD) and heart failure, as well as technology for running decentralised clinical trials.

Hospitals 57

Hospitals 57

pharmaphorum

JANUARY 18, 2022

As it is easy to use – sprayed up the nostrils – it has the potential to be a game-changing prophylactic for people at increased risk of illness – such as older people, those with COPD, and asthmatics. We look forward to updating the market as POLB 002 progresses through the clinic with the ultimate aim of partnering it with Big Pharma.”.

Vaccines 57

Vaccines 57

pharmaphorum

JULY 28, 2022

The drug is also being tested in some forms of chronic obstructive pulmonary disease (COPD), and various conditions leading to urticaria (hives), although it fell short in a phase 3 trial in chronic spontaneous urticaria (CSU) earlier this year. The post Dupixent drives Sanofi to hike its full-year profit forecasts appeared first on.

Vaccines 57

Vaccines 57

pharmaphorum

DECEMBER 14, 2021

It said the company expects to employ 155 clinicians by the middle of next year, who will provide remote care to people with chronic conditions such as hypertension, chronic obstructive pulmonary disease (COPD) and type 2 diabetes. It promises to deliver improved clinical outcomes and a “world-class” patient experience.

Diabetes 52

Diabetes Hospitals 52

pharmaphorum

OCTOBER 4, 2021

The 14 winners are: Guy’s and St Thomas’ NHS Foundation Trust and Royal Devon and Exeter NHS Trust, for a respiratory remote monitoring programme, partnered with patientMpower ; One Health Lewisham for a clinical messaging for hypertension support platform partnered with Doctaly Assist ; Guy’s and St Thomas’ NHS Foundation (..)

Hospitals 111

Hospitals Diabetes 111

Pharmacy Joe

AUGUST 16, 2023

The decision to intubate is often based on clinical experience as much as it is based on objective data. What is the anticipated clinical course? COPD exacerbation, asthma exacerbation, and acute pulmonary edema are examples of conditions where a patient might not be able to oxygenate. Can the patient protect their airway?

Hospitals 52

Hospitals Inpatient Labelling 52

pharmaphorum

JANUARY 12, 2023

Avillion – clinical co-development partner with AZ – conducted the global phase 3 trial of over 4,000 patients across four studies (including the MANDALA and DENALI trials). The new approval continues the company’s unmarred success rate in clinical co-development partnerships across multiple therapeutic areas.

52

52

pharmaphorum

MARCH 18, 2021

The toolkit – or the AMAZE Disease Management Platform to give it its full name – is designed to bring patients with conditions like asthma, chronic obstructive pulmonary disease (COPD), heart failure, chronic kidney disease, and diabetes close to healthcare providers.

Diabetes 89

Diabetes Communication Hospitals 89

pharmaphorum

FEBRUARY 26, 2021

In NAVIGATOR, tezepelumab achieved a 41% reduction in AAER in patients with eosinophil levels below 300 cells/µL, with a clinically meaningful fall in 70% of all patients in that group. There was also a clinically meaningful reduction in 39% of the <150 cells/µL group. Results from that are due in 2023.

67

67

pharmaphorum

SEPTEMBER 18, 2020

Vertex will be responsible for preclinical and clinical development as well as commercial activities should they reach the market. The new project will see Moderna coming up with mRNA drugs coding for gene-editing endonuclease enzymes to be delivered using its LNPs.

Vaccines 104

Vaccines 104

pharmaphorum

JULY 21, 2022

Gefapixant is already approved in Japan as Lyfnua, but Bayer and Bellus are in hot pursuit of the drug in the US with their respective eliapixant and BLU-5937 candidates, which are both in late-stage clinical testing. The post After cough drug setback, Merck partners Hyfe’s tracking app appeared first on.

52

52